Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE 8 phase II trial of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab in first-line metastatic colorectal cancer
2019-004223-20Phase 2Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing trifluridine/tipiracil plus panitumumab with trifluridine/tipiracil plus bevacizumab (2 arms). Primary endpoint: Objective response rate. Started Mar 2021; status: active.
02
Drugs
trifluridinetipiracilpanitumumabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-004223-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004223-20.